Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Windtree Therapeutics ( (WINT) ) has shared an update.
On June 24, 2025, Windtree Therapeutics entered into note purchase agreements with two purchasers, issuing convertible promissory notes totaling $174,419, with proceeds intended for operational expenses. Additionally, the company is disputing a $3 million earnest money claim related to a terminated real estate agreement. On June 25, 2025, Jamie McAndrew resigned as CFO, with CEO Jed Latkin assuming interim financial responsibilities.
The most recent analyst rating on (WINT) stock is a Hold with a $7.00 price target. To see the full list of analyst forecasts on Windtree Therapeutics stock, see the WINT Stock Forecast page.
Spark’s Take on WINT Stock
According to Spark, TipRanks’ AI Analyst, WINT is a Underperform.
Windtree Therapeutics faces significant financial challenges with no revenue and considerable net losses, severely impacting its financial health and stability in the biotechnology sector. The technical analysis suggests bearish momentum, aligning with the weak financials. The negative P/E ratio and lack of dividends make valuation unattractive. Recent corporate events provide a minor positive outlook, but overall, the stock presents considerable risks with limited upside potential without a substantial change in financial performance or market conditions.
To see Spark’s full report on WINT stock, click here.
More about Windtree Therapeutics
Windtree Therapeutics, Inc. operates in the biotechnology industry, focusing on developing innovative therapies for acute cardiovascular and pulmonary conditions.
Average Trading Volume: 2,472,183
Technical Sentiment Signal: Sell
Current Market Cap: $1.35M
For detailed information about WINT stock, go to TipRanks’ Stock Analysis page.